These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25860242)

  • 21. The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations.
    Soysal T; Eskazan AE; Serin I; Sadri S; Keskin D; Ozgur Yurttas N; Berk S; Erdogan Ozunal I; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Ozbek U; Aydin Y
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e377-e384. PubMed ID: 31088736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
    Papaioannou G; Athanasiadou A; Voutiadou G; Gaitatzi M; Batsis I; Touloumenidou T; Anagnostopoulos A
    Cancer Genet; 2011 Dec; 204(12):692-3. PubMed ID: 22285023
    [No Abstract]   [Full Text] [Related]  

  • 24. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.
    Chiaretti S; Vitale A; Vignetti M; Piciocchi A; Fazi P; Elia L; Falini B; Ronco F; Ferrara F; De Fabritiis P; Luppi M; La Nasa G; Tedeschi A; Califano C; Fanin R; Dore F; Mandelli F; Meloni G; Foà R
    Haematologica; 2016 Dec; 101(12):1544-1552. PubMed ID: 27515250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. gDNA Q-PCR for clinical monitoring of CML.
    Porta G; Pagani IS; Pirrone C
    Cell Cycle; 2015; 14(23):3659-60. PubMed ID: 25714683
    [No Abstract]   [Full Text] [Related]  

  • 26. Imatinib is still recommended for frontline therapy for CML.
    Hantel A; Larson RA
    Blood Adv; 2018 Dec; 2(24):3648-3652. PubMed ID: 30587493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy.
    Moro MI; Manrique G; Uriarte R; Díaz L
    Leuk Lymphoma; 2014 Jul; 55(7):1684-6. PubMed ID: 24083818
    [No Abstract]   [Full Text] [Related]  

  • 28. An analysis of strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia with imatinib-resistant mutations.
    Paquin D; Sacco D; Shamshoian J
    Math Biosci; 2015 Apr; 262():117-24. PubMed ID: 25659886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
    Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
    Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Importance of Being Cured: A Chronic Myeloid Leukemia Perspective.
    Raanani P
    Acta Haematol; 2016; 135(3):131-2. PubMed ID: 26535978
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.
    Cai Y; Liu C; Guo Y; Chen X; Zhang L; Chen Y; Zou Y; Yang W; Zhu X
    Int J Hematol; 2021 Mar; 113(3):413-421. PubMed ID: 33386594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
    Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.
    Breccia M; Foà R
    Curr Oncol Rep; 2018 Mar; 20(3):23. PubMed ID: 29511948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
    Breccia M; Efficace F; Colafigli G; Scalzulli E; Di Prima A; Martelli M; Foà R
    Expert Rev Hematol; 2020 Dec; 13(12):1311-1318. PubMed ID: 33205694
    [No Abstract]   [Full Text] [Related]  

  • 35. [IMATINIB INDUCED EDEMA].
    Olshanskiy D; Ben Varon H; Mouallem M
    Harefuah; 2024 Jun; 163(6):397. PubMed ID: 38884296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current treatment of myeloproliferative neoplasias: three scenarios.
    Xicoy B; Zamora L
    Med Clin (Barc); 2020 Feb; 154(4):131-133. PubMed ID: 31351663
    [No Abstract]   [Full Text] [Related]  

  • 37. Persistent suboptimal molecular response in a patient with chronic myelogenous leukemia and Klinefelter syndrome.
    Chakraborty R; Mukkamalla SK; Singam K; Calderon N
    Korean J Intern Med; 2014 Nov; 29(6):827-9. PubMed ID: 25378984
    [No Abstract]   [Full Text] [Related]  

  • 38. Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
    Ángeles-Velázquez JL; Hurtado-Monroy R; Vargas-Viveros P; Carrillo-Muñoz S; Candelaria-Hernández M
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S82-5. PubMed ID: 27521331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive parameters for imatinib failure in patients with chronic myeloid leukemia.
    Lekovic D; Gotic M; Milic N; Zivojinovic B; Jovanovic J; Colovic N; Milosevic V; Bogdanovic A
    Hematology; 2017 Sep; 22(8):460-466. PubMed ID: 28327053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of chronic myeloid leukemia patients treated with imatinib who are potentially eligible for treatment discontinuation by assessing real-life molecular responses on the international scale in a EUTOS-certified lab.
    Heinrichs A; Dessars B; El Housni H; Pluymers W; Peeters K; Benghiat FS; Heimann P
    Leuk Res; 2018 Apr; 67():27-31. PubMed ID: 29425962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.